Difference between revisions of "B-cell acute lymphoblastic leukemia - historical"
m |
Warner-admin (talk | contribs) m (Text replacement - "'''dosing details in manuscript have been reviewed'''" to "'''dosing details in manuscript have been reviewed by our editors'''") |
||
(37 intermediate revisions by 2 users not shown) | |||
Line 3: | Line 3: | ||
[[#top|Back to Top]] | [[#top|Back to Top]] | ||
</div> | </div> | ||
− | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only | + | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the [[B-cell acute lymphoblastic leukemia|main B-ALL page]] for current regimens. |
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
− | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] | + | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div> |
− | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] | + | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> |
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Upfront induction therapy= | =Upfront induction therapy= | ||
− | + | ==Cyclophosphamide, Doxorubicin, L-asparaginase, Vincristine, Prednisolone {{#subobject:6edd1f|Regimen=1}}== | |
− | + | <div class="toccolours" style="background-color:#ee6b6e"> | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | ==Cyclophosphamide, Doxorubicin, L- | ||
− | <div class="toccolours" style="background-color:# | ||
===Regimen {{#subobject:0f2246|Variant=1}}=== | ===Regimen {{#subobject:0f2246|Variant=1}}=== | ||
{| class="wikitable" style="width: 60%; text-align:center;" | {| class="wikitable" style="width: 60%; text-align:center;" | ||
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
− | !style="width: 33%"| | + | !style="width: 33%"|Dates of enrollment |
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
Line 74: | Line 26: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Cyclophosphamide (Cytoxan)]] | + | *[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 29 |
− | *[[Doxorubicin (Adriamycin)]] | + | *[[Doxorubicin (Adriamycin)]] 30 mg/m<sup>2</sup> IV once per day on days 1 to 3, 8 to 10 |
− | *[[Asparaginase (Elspar)|L-Asparaginase]] | + | *[[Asparaginase (Elspar)|L-Asparaginase]] 6000 IU/m<sup>2</sup> IV once per day on days 29 to 35 |
− | + | *[[Vincristine (Oncovin)]] 1.3 mg/m<sup>2</sup> (maximum dose of 2 mg) IV bolus once per day on days 1, 8, 15, 22 | |
− | |||
− | |||
− | < | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | *[[Vincristine (Oncovin)]] | ||
− | |||
− | |||
− | |||
− | < | ||
− | |||
− | |||
− | </ | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Glucocorticoid therapy==== | ====Glucocorticoid therapy==== | ||
− | *[[ | + | *[[Prednisolone (Millipred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 10 |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Supportive therapy==== | ====Supportive therapy==== | ||
− | * | + | *[[:Category:Granulocyte colony-stimulating factors|G-CSF]] 200 mcg/m<sup>2</sup> IV once per day on days 12 to 26 |
− | ''' | + | '''35-day course''' |
</div> | </div> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#cbd5e8"> |
====Subsequent treatment==== | ====Subsequent treatment==== | ||
− | * | + | *Consolidation I (see paper for details) |
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #''' | + | # '''JALSG-ALL93:''' Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S, Kuriyama K, Ohtake S, Yagasaki F, Murakami H, Asou N, Ino T, Okamoto T, Usui N, Nishimura M, Shinagawa K, Fukushima T, Taguchi H, Morii T, Mizuta S, Akiyama H, Nakamura Y, Ohshima T, Ohno R. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia. 2002 Jul;16(7):1259-66. [https://doi.org/10.1038/sj.leu.2402526 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/12094249/ PubMed] |
− | + | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
==Idarubicin, L-Asparaginase, Vincristine, Prednisone {{#subobject:54jbs9|Regimen=1}}== | ==Idarubicin, L-Asparaginase, Vincristine, Prednisone {{#subobject:54jbs9|Regimen=1}}== | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:3y2de2|Variant=1}}=== | ===Regimen {{#subobject:3y2de2|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
Line 248: | Line 60: | ||
|- | |- | ||
|} | |} | ||
+ | ''Note: This is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.'' | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Idarubicin (Idamycin)]] | + | *[[Idarubicin (Idamycin)]] 5 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 |
− | *[[Asparaginase (Elspar)]] | + | *[[Asparaginase (Elspar)]] 7500 IU/m<sup>2</sup> IV once per day on days 10, 13, 16, 19, 22, 25 |
− | *[[Vincristine (Oncovin)]] | + | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 |
====Glucocorticoid therapy==== | ====Glucocorticoid therapy==== | ||
− | *[[Prednisone (Sterapred)]] IV | + | *[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO or IV once per day on days 1 to 21 |
+ | '''35-day course''' | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''GOELAL02:''' Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F, Lamy T, Pignon B, Jouet JP, Garidi R, Caillot D, Berthou C, Guyotat D, Sadoun A, Sotto JJ, Lioure B, Casassus P, Solal-Celigny P, Stalnikiewicz L, Audhuy B, Blanchet O, Baranger L, Béné MC, Ifrah N; GOELAMS (Groupe Ouest-Est des Leucémies Airguës et Maladies du Sang) Group. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 2004 Nov 15;104(10):3028-37. Epub 2004 Jul 15. [https://doi.org/10.1182/blood-2003-10-3560 link to original article] | + | #'''GOELAL02:''' Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F, Lamy T, Pignon B, Jouet JP, Garidi R, Caillot D, Berthou C, Guyotat D, Sadoun A, Sotto JJ, Lioure B, Casassus P, Solal-Celigny P, Stalnikiewicz L, Audhuy B, Blanchet O, Baranger L, Béné MC, Ifrah N; GOELAMS (Groupe Ouest-Est des Leucémies Airguës et Maladies du Sang) Group. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 2004 Nov 15;104(10):3028-37. Epub 2004 Jul 15. [https://doi.org/10.1182/blood-2003-10-3560 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/15256423/ PubMed] [https://clinicaltrials.gov/study/NCT00483132 NCT00483132] |
− | + | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
==L-Asparaginase, Vincristine, Prednisone {{#subobject:d039d8|Regimen=1}}== | ==L-Asparaginase, Vincristine, Prednisone {{#subobject:d039d8|Regimen=1}}== | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:a4174a|Variant=1}}=== | ===Regimen {{#subobject:a4174a|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|[https://doi.org/10.1016/0145-2126(79)90036-5 Henderson et al. 1979 (CALGB 7113)] | |[https://doi.org/10.1016/0145-2126(79)90036-5 Henderson et al. 1979 (CALGB 7113)] | ||
Line 362: | Line 89: | ||
| style="background-color:#d3d3d3" | | | style="background-color:#d3d3d3" | | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1182/blood.V64.1.267.267 Gottlieb et al. 1984 (CALGB 7612)] |
|1976-1980 | |1976-1980 | ||
|style="background-color:#1a9851"|Randomized (C) | |style="background-color:#1a9851"|Randomized (C) | ||
|[[B-cell_acute_lymphoblastic_leukemia#DOLP|DOLP]] | |[[B-cell_acute_lymphoblastic_leukemia#DOLP|DOLP]] | ||
|style="background-color:#d73027"|Inferior CR rate | |style="background-color:#d73027"|Inferior CR rate | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
+ | ''Note: The asparaginase dosing shown here was that after a mid-protocol amendment due to excess toxicity.'' | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Asparaginase (Elspar)]] | + | *[[Asparaginase (Elspar)]] 500 IU/kg IV once per day on days 16 to 25 |
− | *[[Vincristine (Oncovin)]] | + | *[[Vincristine (Oncovin)]] 2 mg IV once per day on days 1, 8, 15 |
====Glucocorticoid therapy==== | ====Glucocorticoid therapy==== | ||
− | *[[Prednisone (Sterapred)]] | + | *[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup>/day PO on days 1 to 21, then tapered off over days 22 to 28 |
'''28-day course''' | '''28-day course''' | ||
− | |||
− | |||
− | |||
− | |||
</div></div> | </div></div> | ||
+ | |||
===References=== | ===References=== | ||
− | + | # '''CALGB 7113:''' Henderson ES, Scharlau C, Cooper MR, Haurani FI, Silver RT, Brunner K, Carey RW, Falkson G, Blom J, Nawabi IV, Levine AS, Bank A, Cuttner J, Cornwell GG 3rd, Henry P, Nissen NI, Wiernik PH, Leone L, Wohl H, Rai K, James GW, Weinberg V, Glidewell O, Holland JF. Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: results of CALGB protocol 7113. Leuk Res. 1979;3(6):395-407. [https://doi.org/10.1016/0145-2126(79)90036-5 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/297176/ PubMed] | |
− | # '''CALGB 7113:''' Henderson ES, Scharlau C, Cooper MR, Haurani FI, Silver RT, Brunner K, Carey RW, Falkson G, Blom J, Nawabi IV, Levine AS, Bank A, Cuttner J, Cornwell GG 3rd, Henry P, Nissen NI, Wiernik PH, Leone L, Wohl H, Rai K, James GW, Weinberg V, Glidewell O, Holland JF. Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: results of CALGB protocol 7113. Leuk Res. 1979;3(6):395-407. [https://doi.org/10.1016/0145-2126(79)90036-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/297176 PubMed] | + | # '''CALGB 7612:''' Gottlieb AJ, Weinberg V, Ellison RR, Henderson ES, Terebelo H, Rafla S, Cuttner J, Silver RT, Carey RW, Levy RN, Hutchinson JL, Raich P, Cooper MR, Wiernik P, Anderson JR, Holland JF. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by Cancer and Leukemia Group B. Blood. 1984 Jul;64(1):267-74. [https://doi.org/10.1182/blood.V64.1.267.267 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6375760/ PubMed] |
− | # '''CALGB 7612:''' Gottlieb AJ, Weinberg V, Ellison RR, Henderson ES, Terebelo H, Rafla S, Cuttner J, Silver RT, Carey RW, Levy RN, Hutchinson JL, Raich P, Cooper MR, Wiernik P, Anderson JR, Holland JF. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by Cancer and Leukemia Group B. Blood. 1984 Jul;64(1):267-74 | + | |
− | |||
− | |||
− | |||
− | |||
− | |||
==Mercaptopurine & Methotrexate {{#subobject:6366a6|Regimen=1}}== | ==Mercaptopurine & Methotrexate {{#subobject:6366a6|Regimen=1}}== | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:1fc958|Variant=1}}=== | ===Regimen {{#subobject:1fc958|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1182/blood.V13.12.1126.1126 Frei et al. 1958 (ALGB 01)] |
− | | | + | |Not reported |
|style="background-color:#1a9851"|Randomized (E-switch-ic) | |style="background-color:#1a9851"|Randomized (E-switch-ic) | ||
|[[#Mercaptopurine_.26_Methotrexate|6-MP & MTX]]; alternate dosing | |[[#Mercaptopurine_.26_Methotrexate|6-MP & MTX]]; alternate dosing | ||
− | |style="background-color:#ffffbf"| | + | |style="background-color:#ffffbf"|Did not meet endpoints |
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1182/blood.V18.4.431.431 Frei et al. 1961 (ALGB 03)] |
|1957-1960 | |1957-1960 | ||
|style="background-color:#1a9851"|Randomized (E-esc) | |style="background-color:#1a9851"|Randomized (E-esc) | ||
− | |1. [[# | + | |1. [[#Mercaptopurine_monotherapy_888|6-MP]]<br>2. [[#Methotrexate_monotherapy_888|MTX]] |
− | |style="background-color:#ffffbf"| | + | |style="background-color:#ffffbf"|Did not meet endpoint of DOR |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
Line 452: | Line 136: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Mercaptopurine (6-MP)]] | + | *[[Mercaptopurine (6-MP)]] 1.5 mg/kg PO twice per day |
− | *[[Methotrexate (MTX)]] | + | *[[Methotrexate (MTX)]] by the following age-based criteria: |
+ | **Less than 2 years old: 1.25 mg PO once per day | ||
+ | **2 to 10 years old: 2.5 mg PO once per day | ||
+ | **Older than 10 years old: 5 mg PO once per day | ||
+ | '''Continued indefinitely''' | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''ALGB 01:''' Frei E 3rd, Holland JF, Schneiderman MA, Pinkel D, Selkirk G, Freireich EJ, Silver RT, Gold GL, Regelson W. A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood. 1958 Dec;13(12):1126-48. [ | + | # '''ALGB 01:''' Frei E 3rd, Holland JF, Schneiderman MA, Pinkel D, Selkirk G, Freireich EJ, Silver RT, Gold GL, Regelson W. A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood. 1958 Dec;13(12):1126-48. [https://doi.org/10.1182/blood.V13.12.1126.1126 link to original article] [https://pubmed.ncbi.nlm.nih.gov/13596417/ PubMed] |
− | # '''ALGB 03:''' Frei E, Freireich EJ, Gehan E, Pinkel D, Holland JF, Selawry O, Haurani F, Spurr CL, Hayes DM, James GW, Rothberg H, Sodee DB, Rundles RW, Schroeder LR, Hoogstraten B, Wolman IJ, Traggis DG, Cooper T, Gendel BR, Ebaugh F, Taylor R. Studies of Sequential and Combination Antimetabolite Therapy in Acute Leukemia: 6-Mercaptopurine and Methotrexate. Blood. 1961;18(4):431-454. [ | + | # '''ALGB 03:''' Frei E, Freireich EJ, Gehan E, Pinkel D, Holland JF, Selawry O, Haurani F, Spurr CL, Hayes DM, James GW, Rothberg H, Sodee DB, Rundles RW, Schroeder LR, Hoogstraten B, Wolman IJ, Traggis DG, Cooper T, Gendel BR, Ebaugh F, Taylor R. Studies of Sequential and Combination Antimetabolite Therapy in Acute Leukemia: 6-Mercaptopurine and Methotrexate. Blood. 1961;18(4):431-454. [https://doi.org/10.1182/blood.V18.4.431.431 link to original article] '''dosing details in manuscript have been reviewed by our editors''' |
− | + | ||
− | == | + | ==Prednisolone monotherapy {{#subobject:5d40b1|Regimen=1}}== |
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
− | ===Regimen {{#subobject: | + | ===Regimen variant #1 {{#subobject:b66a94|Variant=1}}=== |
− | {| class="wikitable sortable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | !style="width: | + | !style="width: 33%"|Study |
− | !style="width: | + | !style="width: 33%"|Dates of enrollment |
− | !style="width: | + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] |
− | |||
− | |||
|- | |- | ||
− | |[https://doi.org/10.1056/ | + | |[https://doi.org/10.1056/NEJM196206282662603 Shanbrom & Miller 1962] |
− | | | + | |Not reported |
− | |style="background-color:# | + | | style="background-color:#91cf61" |Non-randomized |
− | |||
− | |||
|- | |- | ||
|} | |} | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
− | |||
− | |||
====Glucocorticoid therapy==== | ====Glucocorticoid therapy==== | ||
− | *[[ | + | *[[Prednisolone (Millipred)]] 50 mg PO once per day on days 1 to 10 |
− | </div></div> | + | '''10-day course''' |
− | + | </div></div><br> | |
− | + | <div class="toccolours" style="background-color:#ee6b6e"> | |
− | + | ===Regimen variant #2 {{#subobject:b6ee94|Variant=1}}=== | |
− | <div class="toccolours" style="background-color:# | ||
− | ===Regimen {{#subobject: | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
− | !style="width: 33%"| | + | !style="width: 33%"|Dates of enrollment |
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://doi.org/10.1056/NEJM196206282662603 Shanbrom & Miller 1962] | |[https://doi.org/10.1056/NEJM196206282662603 Shanbrom & Miller 1962] | ||
− | | | + | |Not reported |
| style="background-color:#91cf61" |Non-randomized | | style="background-color:#91cf61" |Non-randomized | ||
|- | |- | ||
Line 499: | Line 179: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Glucocorticoid therapy==== | ====Glucocorticoid therapy==== | ||
− | *[[Prednisolone (Millipred)]] | + | *[[Prednisolone (Millipred)]] 500 mg PO once per day on days 1 to 10 |
+ | '''10-day course''' | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Shanbrom E, Miller S. Critical evaluation of massive steroid therapy of acute leukemia. N Engl J Med. 1962 Jun 28;266:1354-8. [https://doi.org/10.1056/NEJM196206282662603 link to original article] [https://pubmed.ncbi.nlm.nih.gov/13911203 PubMed] | + | # Shanbrom E, Miller S. Critical evaluation of massive steroid therapy of acute leukemia. N Engl J Med. 1962 Jun 28;266:1354-8. [https://doi.org/10.1056/NEJM196206282662603 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/13911203/ PubMed] |
+ | |||
==Prednisone monotherapy {{#subobject:5eeb7e|Regimen=1}}== | ==Prednisone monotherapy {{#subobject:5eeb7e|Regimen=1}}== | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
− | ===Regimen {{#subobject:07e67b|Variant=1}}=== | + | ===Regimen variant #1 {{#subobject:07e67b|Variant=1}}=== |
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
− | !style="width: 33%"| | + | !style="width: 33%"|Dates of enrollment |
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
Line 518: | Line 200: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Glucocorticoid therapy==== | ====Glucocorticoid therapy==== | ||
− | *[[Prednisone (Sterapred)]] | + | *[[Prednisone (Sterapred)]] 125 mg PO twice per day on days 1 to 14, then tapered |
− | </div></div> | + | '''One course''' |
− | + | </div></div><br> | |
− | + | <div class="toccolours" style="background-color:#ee6b6e"> | |
− | + | ===Regimen variant #2 {{#subobject:4te67b|Variant=1}}=== | |
− | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" | |
− | <div class="toccolours" style="background-color:# | + | !style="width: 33%"|Study |
− | ===Regimen {{#subobject: | + | !style="width: 33%"|Dates of enrollment |
− | {| class="wikitable sortable" style="width: | + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] |
− | !style="width: | ||
− | !style="width: | ||
− | !style="width: | ||
− | |||
− | |||
|- | |- | ||
− | |[https://doi.org/10.1056/ | + | |[https://doi.org/10.1056/NEJM195807312590502 Granville et al. 1958] |
− | | | + | |1955-1956 |
− | |style="background-color:# | + | | style="background-color:#91cf61" |Non-randomized |
− | |||
− | |||
|- | |- | ||
|} | |} | ||
− | |||
− | |||
− | |||
− | |||
− | |||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
− | ==== | + | ====Glucocorticoid therapy==== |
− | *[[ | + | *[[Prednisone (Sterapred)]] 250 mg PO four times per day on days 1 to 14, then tapered |
− | + | '''One course''' | |
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # | + | # Granville NB, Rubio F Jr, Unugur A, Schulman E, Dameshek W. Treatment of acute leukemia in adults with massive doses of prednisone and prednisolone. N Engl J Med. 1958 Jul 31;259(5):207-13. [https://doi.org/10.1056/NEJM195807312590502 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/13566450/ PubMed] |
+ | |||
=Late intensification= | =Late intensification= | ||
==POMP {{#subobject:31219|Regimen=1}}== | ==POMP {{#subobject:31219|Regimen=1}}== | ||
POMP: '''<u>P</u>'''urinethol (Mercaptopurine), '''<u>O</u>'''ncovin (Vincristine), '''<u>M</u>'''ethotrexate, '''<u>P</u>'''rednisone | POMP: '''<u>P</u>'''urinethol (Mercaptopurine), '''<u>O</u>'''ncovin (Vincristine), '''<u>M</u>'''ethotrexate, '''<u>P</u>'''rednisone | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:93b1b3|Variant=1}}=== | ===Regimen {{#subobject:93b1b3|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
− | !style="width: 33%"| | + | !style="width: 33%"|Dates of enrollment |
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1001/jama.1976.03260360023019 Bodey et al. 1976] |
− | | | + | |1970-03 to 1973-05 |
− | | style="background-color:#ffffbe" |Non-randomized, | + | | style="background-color:#ffffbe" |Non-randomized, fewer than 20 pts |
|- | |- | ||
|} | |} | ||
Line 570: | Line 241: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Mercaptopurine (6-MP)]] | + | *[[Mercaptopurine (6-MP)]] 500 mg/m<sup>2</sup> IV once per day on days 1 to 5 |
− | *[[Vincristine (Oncovin)]] | + | *[[Vincristine (Oncovin)]] 2 mg IV once on day 1 |
− | *[[Methotrexate (MTX)]] | + | *[[Methotrexate (MTX)]] 7.5 mg/m<sup>2</sup> IV once per day on days 1 to 5 |
====Glucocorticoid therapy==== | ====Glucocorticoid therapy==== | ||
− | *[[Prednisone (Sterapred)]] | + | *[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5 |
− | + | '''One course''' | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # | + | # Bodey GP, Freireich EJ, Gehan E, McCredie KB, Rodriguez V, Gutterman J, Burgess MA. Late intensification therapy for acute leukemia in remission: chemotherapy and immunotherapy. JAMA. 1976 Mar 8;235(10):1021-5. [https://doi.org/10.1001/jama.1976.03260360023019 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/946184/ PubMed] |
− | + | ||
=Relapsed or refractory= | =Relapsed or refractory= | ||
− | == | + | ==BCG vaccine monotherapy {{#subobject:e05416|Regimen=1}}== |
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:637e03|Variant=1}}=== | ===Regimen {{#subobject:637e03|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
− | !style="width: 33%"| | + | !style="width: 33%"|Dates of enrollment |
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://doi.org/10.1016/s0140-6736(69)92648-8 Mathé et al. 1969] | |[https://doi.org/10.1016/s0140-6736(69)92648-8 Mathé et al. 1969] | ||
− | | | + | |Not reported |
| style="background-color:#91cf61" |Non-randomized | | style="background-color:#91cf61" |Non-randomized | ||
|- | |- | ||
Line 629: | Line 267: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Immunotherapy==== | ====Immunotherapy==== | ||
− | *[[ | + | *[[BCG vaccine]] |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # | + | # Mathé G, Amiel JL, Schwarzenberg L, Schneider M, Cattan A, Schlumberger JR, Hayat M, De Vassal F. Active immunotherapy for acute lymphoblastic leukaemia. Lancet. 1969 Apr 5;1(7597):697-9. [https://doi.org/10.1016/s0140-6736(69)92648-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/4182654/ PubMed] |
+ | |||
==Pentostatin monotherapy {{#subobject:aa19e0|Regimen=1}}== | ==Pentostatin monotherapy {{#subobject:aa19e0|Regimen=1}}== | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:19d2c6|Variant=1}}=== | ===Regimen {{#subobject:19d2c6|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
− | !style="width: 33%"| | + | !style="width: 33%"|Dates of enrollment |
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://doi.org/10.1016/S0140-6736(81)91491-4 Prentice et al. 1981] | |[https://doi.org/10.1016/S0140-6736(81)91491-4 Prentice et al. 1981] | ||
− | | | + | |Not reported |
| style="background-color:#ffffbe" |Pilot | | style="background-color:#ffffbe" |Pilot | ||
|- | |- | ||
Line 717: | Line 290: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Prentice HG, Russell NH, Lee N, Ganeshaguru K, Blacklock H, Piga A, Smyth JF, Hoffbrand AV. Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia. Lancet. 1981 Dec 5;2(8258):1250-4. [https://doi.org/10.1016/S0140-6736(81)91491-4 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6118669 PubMed] | + | # Prentice HG, Russell NH, Lee N, Ganeshaguru K, Blacklock H, Piga A, Smyth JF, Hoffbrand AV. Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia. Lancet. 1981 Dec 5;2(8258):1250-4. [https://doi.org/10.1016/S0140-6736(81)91491-4 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6118669/ PubMed] |
==TBI, then auto HSCT {{#subobject:1a2735|Regimen=1}}== | ==TBI, then auto HSCT {{#subobject:1a2735|Regimen=1}}== | ||
TBI: '''<u>T</u>'''otal '''<u>B</u>'''ody '''<u>I</u>'''rradiation | TBI: '''<u>T</u>'''otal '''<u>B</u>'''ody '''<u>I</u>'''rradiation | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:635694|Variant=1}}=== | ===Regimen {{#subobject:635694|Variant=1}}=== | ||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
Line 736: | Line 309: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # McGovern JJ Jr, Russell PS, Atkins L, Webster EW. Treatment of terminal leukemic relapse by total-body irradiation and intravenous infusion of stored autologous bone marrow obtained during remission. N Engl J Med. 1959 Apr 2;260(14):675-83. [https://doi.org/10.1056/NEJM195904022601401 link to original article] [https://pubmed.ncbi.nlm.nih.gov/13644566 PubMed] | + | # McGovern JJ Jr, Russell PS, Atkins L, Webster EW. Treatment of terminal leukemic relapse by total-body irradiation and intravenous infusion of stored autologous bone marrow obtained during remission. N Engl J Med. 1959 Apr 2;260(14):675-83. [https://doi.org/10.1056/NEJM195904022601401 link to original article] [https://pubmed.ncbi.nlm.nih.gov/13644566/ PubMed] |
==Vincristine liposomal monotherapy {{#subobject:f19406|Regimen=1}}== | ==Vincristine liposomal monotherapy {{#subobject:f19406|Regimen=1}}== | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:18f662|Variant=1}}=== | ===Regimen {{#subobject:18f662|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 80%; text-align:center;" | {| class="wikitable sortable" style="width: 80%; text-align:center;" | ||
!style="width: 25%"|Study | !style="width: 25%"|Study | ||
− | !style="width: 25%"| | + | !style="width: 25%"|Dates of enrollment |
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979201/ O'Brien et al. 2012 (RALLY)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979201/ O'Brien et al. 2012 (RALLY)] | ||
− | |2007 | + | |2007 to not reported |
|style="background-color:#91cf61"|Phase 2 (RT) | |style="background-color:#91cf61"|Phase 2 (RT) | ||
|ORR: 35% | |ORR: 35% | ||
Line 754: | Line 327: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Vincristine liposomal (Marqibo)]] 2.25 mg/m<sup>2</sup> IV over 60 minutes once | + | *[[Vincristine liposomal (Marqibo)]] 2.25 mg/m<sup>2</sup> IV over 60 minutes once on day 1 |
− | ''' | + | '''7-day cycles''' |
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''RALLY:''' O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D, Heffner LT, Larson M, Seiter K, Smith S, Assouline S, Kuriakose P, Maness L, Nagler A, Rowe J, Schaich M, Shpilberg O, Yee K, Schmieder G, Silverman JA, Thomas D, Deitcher SR, Kantarjian H. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013 Feb 20;31(6):676-83. Epub 2012 Nov 19. [https://doi.org/10.1200/jco.2012.46.2309 link to original article] ''' | + | # '''RALLY:''' O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D, Heffner LT, Larson M, Seiter K, Smith S, Assouline S, Kuriakose P, Maness L, Nagler A, Rowe J, Schaich M, Shpilberg O, Yee K, Schmieder G, Silverman JA, Thomas D, Deitcher SR, Kantarjian H. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013 Feb 20;31(6):676-83. Epub 2012 Nov 19. [https://doi.org/10.1200/jco.2012.46.2309 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979201/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23169518/ PubMed] [https://clinicaltrials.gov/study/NCT00495079 NCT00495079] |
[[Category:B-cell acute lymphoblastic leukemia regimens]] | [[Category:B-cell acute lymphoblastic leukemia regimens]] | ||
[[Category:Historical regimens]] | [[Category:Historical regimens]] |
Latest revision as of 12:17, 15 July 2024
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main B-ALL page for current regimens.
11 regimens on this page
13 variants on this page
|
Upfront induction therapy
Cyclophosphamide, Doxorubicin, L-asparaginase, Vincristine, Prednisolone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Takeuchi et al. 2002 (JALSG-ALL93) | 1993-1997 | Non-randomized |
Chemotherapy
- Cyclophosphamide (Cytoxan) 600 mg/m2 IV once on day 29
- Doxorubicin (Adriamycin) 30 mg/m2 IV once per day on days 1 to 3, 8 to 10
- L-Asparaginase 6000 IU/m2 IV once per day on days 29 to 35
- Vincristine (Oncovin) 1.3 mg/m2 (maximum dose of 2 mg) IV bolus once per day on days 1, 8, 15, 22
Glucocorticoid therapy
- Prednisolone (Millipred) 40 mg/m2 PO once per day on days 1 to 10
Supportive therapy
- G-CSF 200 mcg/m2 IV once per day on days 12 to 26
35-day course
Subsequent treatment
- Consolidation I (see paper for details)
References
- JALSG-ALL93: Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S, Kuriyama K, Ohtake S, Yagasaki F, Murakami H, Asou N, Ino T, Okamoto T, Usui N, Nishimura M, Shinagawa K, Fukushima T, Taguchi H, Morii T, Mizuta S, Akiyama H, Nakamura Y, Ohshima T, Ohno R. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia. 2002 Jul;16(7):1259-66. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Idarubicin, L-Asparaginase, Vincristine, Prednisone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hunault et al. 2004 (GOELAL02) | 1994-1998 | Phase 3 (C) | Idarubicin, L-asparaginase, Vincristine, Prednisone; oral prednisone | Did not meet primary endpoint of response rate |
Note: This is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.
Chemotherapy
- Idarubicin (Idamycin) 5 mg/m2 IV once per day on days 1, 8, 15, 22
- Asparaginase (Elspar) 7500 IU/m2 IV once per day on days 10, 13, 16, 19, 22, 25
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 1, 8, 15, 22
Glucocorticoid therapy
- Prednisone (Sterapred) 40 mg/m2 PO or IV once per day on days 1 to 21
35-day course
References
- GOELAL02: Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F, Lamy T, Pignon B, Jouet JP, Garidi R, Caillot D, Berthou C, Guyotat D, Sadoun A, Sotto JJ, Lioure B, Casassus P, Solal-Celigny P, Stalnikiewicz L, Audhuy B, Blanchet O, Baranger L, Béné MC, Ifrah N; GOELAMS (Groupe Ouest-Est des Leucémies Airguës et Maladies du Sang) Group. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 2004 Nov 15;104(10):3028-37. Epub 2004 Jul 15. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00483132
L-Asparaginase, Vincristine, Prednisone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Henderson et al. 1979 (CALGB 7113) | 1971-1976 | Non-randomized | ||
Gottlieb et al. 1984 (CALGB 7612) | 1976-1980 | Randomized (C) | DOLP | Inferior CR rate |
Note: The asparaginase dosing shown here was that after a mid-protocol amendment due to excess toxicity.
Chemotherapy
- Asparaginase (Elspar) 500 IU/kg IV once per day on days 16 to 25
- Vincristine (Oncovin) 2 mg IV once per day on days 1, 8, 15
Glucocorticoid therapy
- Prednisone (Sterapred) 40 mg/m2/day PO on days 1 to 21, then tapered off over days 22 to 28
28-day course
References
- CALGB 7113: Henderson ES, Scharlau C, Cooper MR, Haurani FI, Silver RT, Brunner K, Carey RW, Falkson G, Blom J, Nawabi IV, Levine AS, Bank A, Cuttner J, Cornwell GG 3rd, Henry P, Nissen NI, Wiernik PH, Leone L, Wohl H, Rai K, James GW, Weinberg V, Glidewell O, Holland JF. Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: results of CALGB protocol 7113. Leuk Res. 1979;3(6):395-407. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- CALGB 7612: Gottlieb AJ, Weinberg V, Ellison RR, Henderson ES, Terebelo H, Rafla S, Cuttner J, Silver RT, Carey RW, Levy RN, Hutchinson JL, Raich P, Cooper MR, Wiernik P, Anderson JR, Holland JF. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by Cancer and Leukemia Group B. Blood. 1984 Jul;64(1):267-74. link to original article PubMed
Mercaptopurine & Methotrexate
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Frei et al. 1958 (ALGB 01) | Not reported | Randomized (E-switch-ic) | 6-MP & MTX; alternate dosing | Did not meet endpoints |
Frei et al. 1961 (ALGB 03) | 1957-1960 | Randomized (E-esc) | 1. 6-MP 2. MTX |
Did not meet endpoint of DOR |
Note: this is one of the first combination regimens in hematology/oncology.
Chemotherapy
- Mercaptopurine (6-MP) 1.5 mg/kg PO twice per day
- Methotrexate (MTX) by the following age-based criteria:
- Less than 2 years old: 1.25 mg PO once per day
- 2 to 10 years old: 2.5 mg PO once per day
- Older than 10 years old: 5 mg PO once per day
Continued indefinitely
References
- ALGB 01: Frei E 3rd, Holland JF, Schneiderman MA, Pinkel D, Selkirk G, Freireich EJ, Silver RT, Gold GL, Regelson W. A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood. 1958 Dec;13(12):1126-48. link to original article PubMed
- ALGB 03: Frei E, Freireich EJ, Gehan E, Pinkel D, Holland JF, Selawry O, Haurani F, Spurr CL, Hayes DM, James GW, Rothberg H, Sodee DB, Rundles RW, Schroeder LR, Hoogstraten B, Wolman IJ, Traggis DG, Cooper T, Gendel BR, Ebaugh F, Taylor R. Studies of Sequential and Combination Antimetabolite Therapy in Acute Leukemia: 6-Mercaptopurine and Methotrexate. Blood. 1961;18(4):431-454. link to original article dosing details in manuscript have been reviewed by our editors
Prednisolone monotherapy
Regimen variant #1
Study | Dates of enrollment | Evidence |
---|---|---|
Shanbrom & Miller 1962 | Not reported | Non-randomized |
Regimen variant #2
Study | Dates of enrollment | Evidence |
---|---|---|
Shanbrom & Miller 1962 | Not reported | Non-randomized |
Glucocorticoid therapy
- Prednisolone (Millipred) 500 mg PO once per day on days 1 to 10
10-day course
References
- Shanbrom E, Miller S. Critical evaluation of massive steroid therapy of acute leukemia. N Engl J Med. 1962 Jun 28;266:1354-8. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Prednisone monotherapy
Regimen variant #1
Study | Dates of enrollment | Evidence |
---|---|---|
Granville et al. 1958 | 1955-1956 | Non-randomized |
Glucocorticoid therapy
- Prednisone (Sterapred) 125 mg PO twice per day on days 1 to 14, then tapered
One course
Regimen variant #2
Study | Dates of enrollment | Evidence |
---|---|---|
Granville et al. 1958 | 1955-1956 | Non-randomized |
Glucocorticoid therapy
- Prednisone (Sterapred) 250 mg PO four times per day on days 1 to 14, then tapered
One course
References
- Granville NB, Rubio F Jr, Unugur A, Schulman E, Dameshek W. Treatment of acute leukemia in adults with massive doses of prednisone and prednisolone. N Engl J Med. 1958 Jul 31;259(5):207-13. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Late intensification
POMP
POMP: Purinethol (Mercaptopurine), Oncovin (Vincristine), Methotrexate, Prednisone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Bodey et al. 1976 | 1970-03 to 1973-05 | Non-randomized, fewer than 20 pts |
Note: POMP is still used in maintenance settings; this is marked historic because it is late intensification.
Chemotherapy
- Mercaptopurine (6-MP) 500 mg/m2 IV once per day on days 1 to 5
- Vincristine (Oncovin) 2 mg IV once on day 1
- Methotrexate (MTX) 7.5 mg/m2 IV once per day on days 1 to 5
Glucocorticoid therapy
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
One course
References
- Bodey GP, Freireich EJ, Gehan E, McCredie KB, Rodriguez V, Gutterman J, Burgess MA. Late intensification therapy for acute leukemia in remission: chemotherapy and immunotherapy. JAMA. 1976 Mar 8;235(10):1021-5. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Relapsed or refractory
BCG vaccine monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Mathé et al. 1969 | Not reported | Non-randomized |
Immunotherapy
References
- Mathé G, Amiel JL, Schwarzenberg L, Schneider M, Cattan A, Schlumberger JR, Hayat M, De Vassal F. Active immunotherapy for acute lymphoblastic leukaemia. Lancet. 1969 Apr 5;1(7597):697-9. link to original article PubMed
Pentostatin monotherapy
References
- Prentice HG, Russell NH, Lee N, Ganeshaguru K, Blacklock H, Piga A, Smyth JF, Hoffbrand AV. Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia. Lancet. 1981 Dec 5;2(8258):1250-4. link to original article PubMed
TBI, then auto HSCT
TBI: Total Body Irradiation
Regimen
Study | Evidence |
---|---|
McGovern et al. 1959 | Pilot |
Note: This is of historic interest and likely the first reported use of autologous HSCT in the treatment of malignancy.
Radiotherapy
References
- McGovern JJ Jr, Russell PS, Atkins L, Webster EW. Treatment of terminal leukemic relapse by total-body irradiation and intravenous infusion of stored autologous bone marrow obtained during remission. N Engl J Med. 1959 Apr 2;260(14):675-83. link to original article PubMed
Vincristine liposomal monotherapy
Regimen
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
O'Brien et al. 2012 (RALLY) | 2007 to not reported | Phase 2 (RT) | ORR: 35% |
Chemotherapy
- Vincristine liposomal (Marqibo) 2.25 mg/m2 IV over 60 minutes once on day 1
7-day cycles
References
- RALLY: O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D, Heffner LT, Larson M, Seiter K, Smith S, Assouline S, Kuriakose P, Maness L, Nagler A, Rowe J, Schaich M, Shpilberg O, Yee K, Schmieder G, Silverman JA, Thomas D, Deitcher SR, Kantarjian H. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013 Feb 20;31(6):676-83. Epub 2012 Nov 19. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00495079